DTIL - Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

• Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today.
• One of the biggest gainers -- up more than 30% -- is Alaunos Therapeutics ( NASDAQ: TCRT ), which is involved with developing T-cell receptor therapies.
• Others in the space with significant upside today include Homology Medicines ( NASDAQ: FIXX ), up 19% (human hematopoietic stem cell derived adeno-associated virus vectors technology) and Adaptimmune Therapeutics ( NASDAQ: ADAP ), up 11% (specific peptide enhanced affinity receptor (SPEAR) T-cell platform), and Precision BioSciences ( DTIL ), up 9% (CAR-T therapies).
• See why Seeking Alpha contributor Terry Chrisomalis calls Adaptimmnune ( ADAP ) an "underappreciated biotech."

For further details see: